Semaglutide
GLP-1 agonist • once-weekly
Human Evidence
Mechanistic Support
Observable Outcomes
Established Use
RESEARCH PATHWAY
Weight & Metabolic Health
Compounds studied for appetite regulation, glucose handling, fat metabolism, and body composition. Ranked here by evidence, not by marketing—from FDA-approved incretins to early-stage metabolic research.
Compounds in this pathway
Each compound is scored with the same BLP Evidence Framework. How scoring works →
Established
Tirzepatide
Dual agonist • GIP/GLP-1
Human Evidence
Mechanistic Support
Observable Outcomes
Established Use
Retatrutide
Triple agonist • GLP-1/GIP/glucagon
Human Evidence
Mechanistic Support
Observable Outcomes
Established Use
Tesamorelin
Visceral fat • GH release
Human Evidence
Mechanistic Support
Observable Outcomes
Established Use
Cagrilintide
Satiety • long-acting amylin
Human Evidence
Mechanistic Support
Observable Outcomes
Established Use
LIPO-C
Lipotropic blend • MIC + carnitine + B3/B5
Human Evidence
Mechanistic Support
Observable Outcomes
Established Use
5-Amino-1MQ
Fat metabolism • NAD+ support
Human Evidence
Mechanistic Support
Observable Outcomes
Established Use
SLU-PP-332
Exercise mimetic • endurance
Human Evidence
Mechanistic Support
Observable Outcomes
Established Use